TGR Analysis in Phase I Clinical Trials—Letter

R. Dienstmann,J. Tabernero
DOI: https://doi.org/10.1158/1078-0432.CCR-13-3455
IF: 13.801
2014-05-01
Clinical Cancer Research
Abstract:There is considerable current interest in defining more precise measurements of experimental drug efficacy. Ferte and colleagues from Institute Gustave Roussy must be acknowledged for the innovative work on tumor growth rate (TGR) reduction as an early indicator of antitumor efficacy in phase I
What problem does this paper attempt to address?